Search dm+d | Analyse prescribing for this drug | See prices paid for this drug and its variants
Name | Rifaximin 550mg tablets |
BNF code | 0501070X0AAABAB |
Virtual Therapeutic Moiety | Rifaximin |
Date identifier became valid | 9 Jun 2023 |
Previous product identifier | 445522003 |
Basis of preferred name | rINN - Recommended International Non-proprietary |
Prescribing status | Valid as a prescribable product |
Sugar free | ✗ |
Gluten free | ✗ |
Preservative free | ✗ |
CFC free | ✗ |
Dose form | Discrete |
Unit dose form size | 1.000 |
Unit dose form units | tablet |
Unit dose unit of measure | tablet |
Virtual Product Ingredient | |
---|---|
Ingredient | Rifaximin |
Basis of pharmaceutical strength | Based on Ingredient Substance |
Strength value numerator | 550.000 |
Strength value numerator unit | mg |
Ontology Drug Form & Route | |
Form & Route | tablet.oral |
Dose Form | |
Formulation | Oral tablet |
Drug Route | |
Route | Oral |
Controlled Drug Prescribing Information | |
Controlled Drug category | No Controlled Drug Status |
Actual Medicinal Products | |
Targaxan 550mg tablets (CST Pharma Ltd) | |
Targaxan 550mg tablets (Norgine Pharmaceuticals Ltd) | |
Virtual Medicinal Product Packs | |
Rifaximin 550mg tablets 1 tablet | |
Rifaximin 550mg tablets 56 tablet | |
Rifaximin 550mg tablets 60 tablet | |
Rifaximin 550mg tablets 98 tablet |
dm+d data retrieved from TRUD: release NHSBSA_11.2.0_20241118000001, imported on 19th November 2024 at 03:53:26.